Are Lipid-Based Products More Effective for Treating Dry Eye Disease?

NEW ROCHELLE, N.Y. - Nov. 21, 2017 - PRLog -- New treatments for dry eye disease that deliver lipids to the ocular surface are designed to more closely mimic the important tear film lipid layer at the air-water interface in the eye. The range and effectiveness of lipid-based products to treat dry eye disease, including liposome lid sprays, emulsion eye drops, lipid nanoparticles, and lipid-drug conjugates are examined in a new Review article published in Journal of Ocular Pharmacology and Therapeutics, a peer-reviewed journal from Mary Ann Liebert, Inc., publishers (http://www.liebertpub.com/). The article is available free on the Journal of Ocular Pharmacology and Therapeutics (http://online.liebertpub.com/doi/full/10.1089/jop.2017.0052) website.

In the article entitled "Relevance of Lipid-Based Products in the Management of Dry Eye Disease (http://online.liebertpub.com/doi/full/10.1089/jop.2017.0052)," Jean-Sébastien Garrigue and Mourad Amrane, Santen SAS (Evry, France), Marie-Odile Faure, Scientific Consulting For You (Paris, France), Juha Holopainen, University of Helsinki (Finland), and Louis Tong, Singapore Eye Research Institute, describe the favorable tolerability profile of lipid-based therapies. Lipid-based products offer advantages compared to water-based artificial tears. Not only can they provide immediate relief of symptoms, but they may also improve the structure and stability of the tear film lipid layer.

"This is a thorough and timely review addressing an emerging treatment modality for the painful disease of dry eye," says Editor-in-Chief W. Daniel Stamer, PhD, Joseph A. C. Wadsworth Professor of Ophthalmology and Professor of Biomedical Engineering, Duke University, Durham, NC.

About the Journal
Journal of Ocular Pharmacology and Therapeutics (http://www.liebertpub.com/jop) is an authoritative peer-reviewed journal published ten times a year online with open access options and in print. It is the only multidisciplinary, peer-reviewed journal providing basic and clinical research that focuses on biopharmaceuticals that have the potential to prevent, treat, and/or diagnose ocular diseases and disorders. The Journal delivers the latest discoveries in the pharmacokinetics and pharmacodynamics of biopharmaceuticals for the treatment of ophthalmic disorders. Tables of content and a sample issue may be viewed on the Journal of Ocular Pharmacology and Therapeutics (http://www.liebertpub.com/jop) website. Journal of Ocular Pharmacology and Therapeuticsis the official journal of the Association for Ocular Pharmacology and Therapeutics (http://www.aopt.org/).

About the Publisher
Mary Ann Liebert, Inc., publishers (http://www.liebertpub.com/) is a privately held, fully integrated media company known for establishing authoritative peer-reviewed journals in many promising areas of science and biomedical research, including ASSAY and Drug Development Technologies and Population Health Management. Its biotechnology trade magazine, GEN (Genetic Engineering & Biotechnology News), was the first in its field and is today the industry's most widely read publication worldwide. A complete list of the firm's 80 journals, books, and newsmagazines is available on the Mary Ann Liebert, Inc., publishers (http://www.liebertpub.com/) website.

Mary Ann Liebert, Inc.    140 Huguenot Street, New Rochelle, NY 10801   www.liebertpub.com

Phone: (914) 740-2100    (800) M-LIEBERT     Fax (914) 740-2101